One Capsule, Once Daily: Start With ZEPOSIA: The Only Oral Advanced Therapya That Can Be Used Before Biologics1-3
ZEPOSIA 7-Day Titration Schedule1
One Capsule, Once a Day, From the Start
The ZEPOSIA Starter Pack is designed to make the titration easier to follow1
Eligible patients enrolled in ZEPOSIA 360 SupportTM, who have been cleared to begin treatment, and who have not received a sample from their provider, may be provided a Starter Kit that includes a 7-day Starter Pack and a 30-day supply of ZEPOSIA.
Initiate ZEPOSIA with a 7-day titration schedule. After initial titration, the recommended once-daily dosage of ZEPOSIA is 0.92 mg taken orally, starting on Day 8.1
An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular (AV) conduction delays may occur1
ZEPOSIA can be taken with or without food1
The ZEPOSIA Starter Pack is designed to make the titration easier to follow1
Additional Dosing Considerations
If a dose of ZEPOSIA is missed during the first 2 weeks of treatment, reinitiate treatment using the titration regimen1
If a dose of ZEPOSIA is missed after the first 2 weeks of treatment, continue with the treatment as planned1
aAdvanced therapies include S1P, biologics, and JAKi.
Starting Patients on ZEPOSIA
Screening for All Patients Prior to First Dose1
Obtain blood work (within the last 6 months)
Complete blood count (CBC), including lymphocyte count (within the last 6 months or after discontinuation of prior UC therapy)
Transaminase and total bilirubin levels
Obtain a one-time electrocardiogram (ECG) to determine whether pre-existing conduction abnormalities are presentb
ZEPOSIA is contraindicated in patients who have the presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.1
Screening for Select Patients Prior to First Dose1
If there is a history of uveitis, macular edema, or diabetes mellitus then ophthalmic evaluation of the fundus, including the macula, must be completedc
If there is no documentation of history of varicella-zoster virus (VZV)/chicken pox, or documentation of a full course of vaccination, then test for antibodiesd
If live attenuated immunizations are required, administer at least 1 month prior to initiation
Evaluate current and prior medications before initiation of treatment1
Support provided by Bristol Myers Squibb at the Homes of Eligible Patientse
Blood work
ECG with cardiologist overread
Macular edema screening with licensed eye clinician overread
VZV antibody testing
The full Prescribing Information for ZEPOSIA does not require routine lab monitoring unless clinically indicated
bIn patients with certain preexisting conditions, advice from a cardiologist should be sought—see Warnings and Precautions in Prescribing Information. ZEPOSIA was not studied in patients who had: Cardiac conduction or rhythm disorders, including sick sinus syndrome, significant QT prolongation (QTcF >450 msec in males, >470 msec in females), risk factors for QT prolongation, or other conduction abnormalities or cardiac condition that in the opinion of the treating investigator could jeopardize the patient's health.1
cPatients with a history of uveitis and patients with a history of diabetes mellitus are at increased risk of macular edema during ZEPOSIA therapy. The incidence of macular edema is also increased in patients with a history of uveitis. In addition to the examination of the fundus, including the macula, prior to treatment, patients with diabetes mellitus or a history of uveitis should have regular follow-up examinations.1
dVZV vaccination of antibody-negative patients is recommended prior to commencing treatment.1
eHome visits for initial routine medical tests are not available to patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or to patients living in Rhode Island.
AV=atrioventricular; BPM=beats per minute; CBC=complete blood count;
ECG=electrocardiogram; HR=heart rate; JAKi=janus kinase inhibitor; QT=an extended interval between the heart contracting and relaxing;
QTcF=corrected QT interval by Fridericia; UC=ulcerative colitis; VZV=varicella-zoster virus.
Get Your Patients Started on ZEPOSIA
Patient Start Form
Enroll patients in ZEPOSIA 360 SupportTM and help them get started on treatment.
Get Started With
To begin the process online, click the button below to visit covermymeds.com
The Only Oral Advanced Therapya That Can Be Used Before Biologics in Patients with Moderate-to-Severe UC1-3
ZEPOSIA 7-Day Titration and Dosing Schedule1
Days 1-4
0.23 mg
Once daily
Days 5-7
0.46 mg
Once daily
An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular (AV) conduction delays may occur.1
Following Titration
0.92 mg
Once daily
An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular (AV) conduction delays may occur.1
Additional Dosing Considerations and Initiation Guide
Additional Dosing Considerations
ZEPOSIA can be taken with or without food1
If a dose of ZEPOSIA is missed during the first 2 weeks of treatment, reinitiate treatment using the titration regimen1
If a dose of ZEPOSIA is missed after the first 2 weeks of treatment, continue with the treatment as planned1
Additional Dosing Considerations
ZEPOSIA can be taken with or without food1
If a dose of ZEPOSIA is missed during the first 2 weeks of treatment, reinitiate treatment using the titration regimen1
If a dose of ZEPOSIA is missed after the first 2 weeks of treatment, continue with the treatment as planned1
aAdvanced therapies include S1P, biologics, and JAKi.
3 steps to get your patients started on ZEPOSIA
ENROLL
patients in ZEPOSIA 360 SupportTM via CoverMyMeds®
SCREEN
your patient one time prior to starting ZEPOSIA
INITIATE
ZEPOSIA with the ZEPOSIA starter kit
Going directly through a specialty pharmacy?
Your patients can enroll at covermymeds.com for help with treatment initiation, ongoing one-on-one assistance from dedicated Coordinators, and access and reimbursement support.
Prior to initiating treatment with ZEPOSIA, perform a one-time screening for complete blood count, cardiac evaluation, liver function tests, ophthalmic evaluation, current or prior medications, and vaccinations.
SCREENINGS FOR ALL PATIENTS1:
Obtain blood work (within the last 6 months)
Complete blood count (CBC), including lymphocyte count (within the last 6 months or after discontinuation of prior UC therapy)
Transaminase and total bilirubin levels
Obtain a one-time electrocardiogram (ECG)
To determine whether pre-existing conduction abnormalities are presentb
ZEPOSIA is contraindicated in patients who have the presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.1
SCREENINGS FOR SELECT PATIENTS PRIOR TO FIRST DOSE1:
If there is a history of uveitis, macular edema, or diabetes mellitus, then an ophthalmic evaluation of the fundus, including the macula, must be completedc
If there is no documentation of history of varicella-zoster virus (VZV)/chicken pox, or documentation of a full course vaccination, then test for anitbodiesd
If live attenuated immunizations are required, administer at least 1 month prior to initiation
Evaluate current and prior medications before initiation of treatment1
bIn patients with certain preexisting conditions, advice from a cardiologist should be sought—see Warnings and Precautions in Prescribing Information. ZEPOSIA was not studied in patients who had: Cardiac conduction or rhythm disorders, including sick sinus syndrome, significant QT prolongation (QTcF >450 msec in males, >470 msec in females), risk factors for QT prolongation, or other conduction abnormalities or cardiac condition that in the opinion of the treating investigator could jeopardize the patient’s health.1
cPatients with a history of uveitis and patients with a history of diabetes mellitus are at increased risk of macular edema during ZEPOSIA therapy. The incidence of macular edema is also increased in patients with a history of uveitis. In addition to the examination of the fundus, including the macula, prior to treatment, patients with diabetes mellitus or a history of uveitis should have regular follow-up examinations.1
dVZV vaccination of antibody-negative patients is recommended prior to commencing treatment.1
AV=atrioventricular; CBC=complete blood count; ECG=electrocardiogram; QT=an extended interval between the heart contracting and relaxing; QTcF=corrected QT interval by Fridericia; UC=ulcerative colitis; VZV=varicella-zoster virus.
BMS wants to ensure your patients have access to everything they need to get started on ZEPOSIA. Eligible commercially insured patients are qualified for in-home, nationwide, baseline assessments with scheduling and appointments available 7 days per week.e
This includes:
Blood work
ECG with cardiologist overread
Macular edema screening with licensed eye clinician overread
VZV antibody testing
An HCP can request in-home services through the CoverMyMeds® portal or by checking the appropriate box on the Start Form for patients.
eHome visits for initial routine medical tests are not available to patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or to patients living in Rhode Island.
Initiate ZEPOSIA with a 7-day titration schedule. After initial titration, the recommended once-daily dosage of ZEPOSIA is 0.92 mg taken orally, starting on Day 8.1
An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular (AV) conduction delays may occur.1
Your patients can receive a free 28-day Starter Kit that includes a 7-day Starter Pack through the ZEPOSIA 360 SupportTM Program.
Initiate ZEPOSIA with a 7-day titration schedule. After initial titration, the recommended once-daily dosage of ZEPOSIA is 0.92 mg taken orally, starting on Day 8.1
An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular (AV) conduction delays may occur.1
Your patients can receive a free 28-day Starter Kit that includes a 7-day Starter Pack through the ZEPOSIA 360 SupportTM Program.
AV=atrioventricular.
Learn More About the ZEPOSIA 360 SupportTM Program